Nature Biotechnology

Harnessing the unusual biology of bats, researchers aim to turn drug discovery upside-down.

A new era of cancer immunotherapy beckons as γδ T cell trials enter final stage.

T cell receptor bispecific agents provide off-the-shelf therapies for targeting intracellular tumor antigens.

Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.

Companies advance tRNA therapeutics to overcome mutant stoppages in protein synthesis shared by thousands of genetic diseases and cancers.

Companies are deploying regulatory T cells, equipped with CAR and TCR constructs, to suppress immunity — locally and for the long term.

After the vaccine triumphs of Pfizer/BioNTech and Moderna, a raft of startups is developing mRNA, circular RNA and self-amplifying RNA therapeutics.

Companies are designing next-generation antibodies modeled on those taken from unique individuals whose immune systems can neutralize any COVID-19 variant — and related coronaviruses, too.

With late-stage trial success, venture funding and next-generation alpha emitters on the way, targeted radiotherapy drugs are finally “getting the attention they deserve.”